RxSight (RXST) Stock Price, News & Analysis

Company Overview

RxSight, Inc. is a medical technology company focused on improving visual outcomes for patients undergoing cataract surgery. The company develops and commercializes ophthalmic products that allow surgeons to adjust a patient’s vision after surgery rather than relying solely on preoperative measurements and the initial implanted lens.

Its primary products include the RxSight Light Adjustable Lens and the RxSight Light Delivery Device. The lens is implanted during cataract surgery and can be adjusted after surgery through controlled ultraviolet-light treatments delivered by the company’s device. These treatments are intended to help ophthalmologists customize the lens power and optimize a patient’s postoperative vision.

RxSight’s technology is marketed to ophthalmic surgeons, eye-care providers and ambulatory surgery centers. The company is based in Aliso Viejo, California, and serves the United States as well as select international markets through its commercial operations and distribution relationships. Its business is centered on the cataract-surgery market and the adoption of light-adjustable intraocular lens technology.

Key Stats

• Today's Range: $5.17 to $5.36
• 50-Day Range: $4.92 to $7.33
• 52-Week Range: $4.48 to $13.22
• Volume: 1.08 million shs
• Average Volume: 788,241 shs
• Market Capitalization: $216.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.37
• Consensus Rating: Reduce

RxSight Stock Analysis - MarketRank™

RxSight scored higher than 59% of companies evaluated by MarketBeat, and ranked 357th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Reduce

Consensus Rating

RxSight has received a consensus rating of Reduce. The company's average rating score is 1.91, and is based on no strong buy ratings, 2 buy ratings, 6 hold ratings, and 3 sell ratings.

Upside Potential

RxSight has a consensus price target of $8.37, representing about 60.9% upside from its current price of $5.20.

Amount of Analyst Coverage

RxSight has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for RxSight are expected to decrease in the coming year, from ($1.01) to ($1.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of RxSight is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of RxSight is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

RxSight has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

10.36% of the float of RxSight has been sold short.

Short Interest Ratio / Days to Cover

RxSight has a short interest ratio ("days to cover") of 4.63.

Change versus previous month

Short interest in RxSight has recently decreased by 9.02%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

RxSight does not currently pay a dividend.

Dividend Growth

RxSight does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.05

News Sentiment

RxSight has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for RxSight this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, RxSight insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $117,951.00 in company stock.

Percentage Held by Insiders

10.05% of the stock of RxSight is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

78.78% of the stock of RxSight is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/20/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Supplies
• Current Symbol: NASDAQ:RXST
• CIK: 1111485
• Web: www.rxsight.com
• Phone: 949-521-7830
• Fax: N/A
• Employees: 461
• Year Founded: 1997

Price Target and Rating

• Average Price Target for RxSight: $8.37
• High Price Target: $11.00
• Low Price Target: $6.30
• Potential Upside/Downside: +60.9%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.91
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$38.94 million
• Net Margins: -36.80%
• Pretax Margin: -36.71%
• Return on Equity: -17.35%
• Return on Assets: -14.70%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.07
• Quick Ratio: 3.61

Sales & Book Value

• Annual Sales: $134.48 million
• Price / Sales: 1.61
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.70 per share
• Price / Book: 0.78

Miscellaneous

• Outstanding Shares: 41,590,000
• Free Float: 37,413,000
• Market Cap: $216.27 million
• Optionable: Optionable
• Beta: 1.16